FRANKFURT (Reuters) – Germany’s BioNTech is purchasing a German biotech production site from Swiss drugs giant Novartis to boost output of the coronavirus vaccine hopeful it is developing with Pfizer.
The transaction, for which the price tag was not disclosed, is part of a push to prepare for a global roll-out of the pair’s experimental vaccine that could be reviewed by regulators as early as next month, among the first in the Western world.
The facility in the German city of Marburg will be converted to be fully on stream in the first half of 2021 with an annual production capacity up to 750 million doses of the inoculation, based on the so-called messenger RNA (mRNA) technology.
The two companies were previously aiming to supply up to 100 million doses worldwide by the end of this year and an additional 1.3 billion doses by the end of 2021.
The new site, with its 300 staff that will join BioNTech, will allow for a larger 2021 output target but it is not yet clear by how much on balance, a company spokeswoman said.
The biotech firm said the facility will be one of the largest mRNA manufacturing sites in Europe, alongside two of BioNTech’s existing vaccine production sites. Pfizer has at least four production sites in the United States and Europe, it added.
(Reporting by Ludwig Burger and Patricia Weiss, editing by Emma Thomasson)
